Per policy, these drugs are exempt from USP <800> handling requirements under normal circumstances. The following outlines must be followed.
generic (Brand) Route [Packaging: Mfg ⇒ Dispense]
NIOSH Group
valGANciclovir (Valcyte) PO [UD ⇒ UD]
Non - Antineoplastic
Pharmacy: Receiving / Storage / Preparation
Exposure Risk: minimal
• Handling/preparation PPE Requirements: n/a
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: n/a
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport
• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Admin.
Exposure Risk: low
• Handling/administration PPE Requirements: PO- Single CX gloves , tube- double CX gloves and gown , wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal / Spills
• Disposal of Drug Waste: Full- blue bin , trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.
Last updated: Jan. 23, 2023
Renal Adjustment Policy valGANciclovir subject to adjustments by pharmacy.
Hazard.Drug Handling(USP 800) USP<800> Hazardous Drug / Assessment of Risk
(Brand)
• Indications
Comments
(Valcyte©)
• Induction
CrCl 40-59: 450 mg BID
CrCl 25-39: 450 mg daily
CrCl 10-24: 450 mg QOD
CrCl < 10: Avoid use
(Valcyte©)
• Maintenance therapy of CMV or transplant pts.
CrCl 40-59: 450 mg daily
CrCl 25-39: 450 mg QOD
CrCl 10-24: 450 mg twice weekly
CrCl < 10: Avoid use
The following outlines must be followed.
Receiving /
Storage /
Preparation
minimal
Storage /
Admin.
low
Spills